23 / 31
Beneficio de IO tras QT-RT secuencial
•
PACIFIC 6 Phase 2 trial: NTC03693300
• Unresectable, Stage IIIA-B
NSCLC without
progression after definitive
platinum-based
SEQUENTIAL CRT
• 18 years or older
• PS 0-1 cohort 1 (120 pts)
• PS2 cohort 2 (30 pts)
• PD-L1 known
DURVALUMAB 1500 mg
c/4s 24 months
Secondary
endpoint
• PFS
• OS
Primary endpoint
• G3-4 TRAEs
Dudas en CPNM estadio
III irresecable